You are here: Industry Insights > Insulin

News List

FDA approves 510(k) clearance to Ortho’s VITROS Insulin reagent and Calibrators biospectrumasia
June 28, 2017
An important biomarker in diabetes and pre-diabetes testing, the assay is expected to be commercially available for use on all of Ortho's VITROS Immunodiagnostic and Integrated Systems in the U.S. during the third quarter of this year.
Tresiba® Demonstrated No Increased Risk Of Major Cardiovascular Events and Significant Reduction in en-cphi.cn
June 13, 2017
Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba® (insulin degludec injection 100 U/mL) and insulin glargine U100...
Sanofi’s insulin lispro receives CHMP positive opinion to treat diabetes pharmaceutical-technology
May 27, 2017
The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorisation of Sanofi's insulin lispro.
Preventing Cancer and Autism: New Function of the Wonder Drug Metformin in Hot Development en-cphi.cn
May 26, 2017
As is known to all, metformin HCL has been helping patients with Type 2 diabetes control their blood sugar for more than two decades.
New analysis shows Novartis Entresto improves glycemic control among heart failure patients with dia cphi-online
March 21, 2017
New use of insulin was also reduced by 29% among patients taking Entresto compared to enalapril-treated patients.
Eli Lilly India launches Humalog 200U/mL KwikPen financialexpress
March 17, 2017
The pen offers physicians an alternative that allows patients to inject 50 per cent less insulin volume
New economic data finds Novo Nordisk’s insulin degludec most cost effective diabetic treatment europeanpharmaceuticalreview
March 15, 2017
A new health economic analysis of two Phase 3b trials has demonstrated that Novo Nordisk‘s Tresiba (insulin degludec) is a cost-effective option for people living with type 1 and type 2 diabetes compared to insulin glargine U100 (Lantus).
New-generation mealtime insulin approved in Europe cphi-online
January 16, 2017
Novo Nordisk to launch Fiasp in first half of 2017.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page